RESUMO
Generalized pustular psoriasis of pregnancy (GPPP) is a rare and severe condition that may impair the health of the mother and fetus. Effective treatment is essential, as treatment options for GPPP are limited due to concerns about unfavorable pregnancy outcomes. We report the case of a 22-year-old woman with GPPP that was unresponsive to systemic corticosteroids. We effectively treated the condition with infliximab at 30 weeks' gestation with an immediate clinical response and no detected serious adverse events except for an oral herpes infection in the patient and low birth weight in the neonate. Future studies are necessary to evaluate the safety and efficacy of infliximab treatment in GPPP.
Assuntos
Psoríase , Dermatopatias Vesiculobolhosas , Doença Aguda , Doença Crônica , Feminino , Humanos , Infliximab/uso terapêutico , Gravidez , Psoríase/tratamento farmacológico , Adulto JovemRESUMO
Hidradenitis suppurativa (HS) rarely affects pediatric patients. The literature on pediatric HS patients is scarce. This is a cross-sectional study based on case note review or interviews and clinical examination of 140 pediatric patients undergoing secondary or tertiary level care. Patients were predominantly female (75.5%, n = 105) with a median age of 16. 39% reported 1st-degree relative with HS. Median BMI percentile was 88, and 11% were smokers (n = 15). Median modified Sartorius score was 8.5. Notable comorbidities found were acne (32.8%, n = 45), hirsutism (19.3%, n = 27), and pilonidal cysts (16.4%, n = 23). Resorcinol (n = 27) and clindamycin (n = 25) were the most frequently used topical treatments. Patients were treated with tetracycline (n = 32), or oral clindamycin and rifampicin in combination (n = 29). Surgical excision was performed in 18 patients, deroofing in five and incision in seven patients. Obesity seemed to be prominent in the pediatric population and correlated to parent BMI, suggesting a potential for preventive measures for the family. Disease management appeared to be similar to that of adult HS, bearing in mind that the younger the patient, the milder the disease in majority of cases.
Assuntos
Antibacterianos/administração & dosagem , Procedimentos Cirúrgicos Dermatológicos , Hidradenite Supurativa/terapia , Obesidade/epidemiologia , Fumar/epidemiologia , Acne Vulgar/epidemiologia , Administração Cutânea , Administração Oral , Adolescente , Índice de Massa Corporal , Criança , Clindamicina/administração & dosagem , Comorbidade , Estudos Transversais , Quimioterapia Combinada/métodos , Feminino , Hidradenite Supurativa/epidemiologia , Hirsutismo/epidemiologia , Humanos , Masculino , Seio Pilonidal/epidemiologia , Resorcinóis/administração & dosagem , Rifampina/administração & dosagem , Fatores de Risco , Índice de Gravidade de Doença , Tetraciclina/administração & dosagem , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Coexistence of obesity, hypertension, insulin resistance and dyslipidemia is defined as metabolic syndrome (MBS), which is among the important risk indicators for cardiovascular diseases, diabetes and stroke. Smoking and alcohol consumption are the other factors which lead to an increase in the risk of cardiovascular disease. OBJECTIVE: To investigate the prevalence of metabolic syndrome, smoking and alcohol consumption in psoriasis patients and the relationship between disease severity and these factors. METHODS: This cross-sectional study enrolled 563 patients with chronic plaque-type psoriasis, all of which completed a questionnaire and underwent a complete physical examination. Data about MBS components, psoriasis severity/duration, smoking and alcohol consumption, and cardiovascular diseases were recorded. RESULTS: A total of 563 patients with ages ranging from 18 to 78 years were evaluated. Metabolic syndrome was found in 12.6% of the patients [central obesity (38.7%), hypertension (14.3%), dyslipidemia (18.6%), diabetes (9.2%)], while 50.3% had smoking, and 3.3% had alcohol consumption. Patients with metabolic syndrome were older and more likely to have a longer disease duration than those without metabolic syndrome (p<0.05 for each). The prevalence of metabolic syndrome was higher in women than in men. Psoriasis was more severe in patients with central obesity, diabetes and smoking than in those without (p<0.05 for each). STUDY LIMITATIONS: Retrospective design. CONCLUSIONS: Our results indicate that MBS is a risk factor for psoriasis patients with advanced age. The relationship between disease severity and obesity, diabetes, and smoking in psoriasis patients indicates that the patients should be informed about the potential metabolic risks and receive therapies for behavioral changes besides anti-psoriatic treatment in order to minimize these risks.
Assuntos
Consumo de Bebidas Alcoólicas/epidemiologia , Síndrome Metabólica/epidemiologia , Psoríase/epidemiologia , Fumar/epidemiologia , Adolescente , Adulto , Distribuição por Idade , Fatores Etários , Idoso , Consumo de Bebidas Alcoólicas/efeitos adversos , Doenças Cardiovasculares/etiologia , Diabetes Mellitus/epidemiologia , Dislipidemias/complicações , Dislipidemias/epidemiologia , Métodos Epidemiológicos , Feminino , Humanos , Hipertensão/complicações , Hipertensão/epidemiologia , Masculino , Síndrome Metabólica/complicações , Pessoa de Meia-Idade , Obesidade Abdominal/complicações , Obesidade Abdominal/epidemiologia , Psoríase/complicações , Fatores de Risco , Distribuição por Sexo , Fatores Sexuais , Fumar/efeitos adversos , Fatores de Tempo , Turquia/epidemiologia , Adulto JovemRESUMO
Abstract: Background: Coexistence of obesity, hypertension, insulin resistance and dyslipidemia is defined as metabolic syndrome (MBS), which is among the important risk indicators for cardiovascular diseases, diabetes and stroke. Smoking and alcohol consumption are the other factors which lead to an increase in the risk of cardiovascular disease. Objective: To investigate the prevalence of metabolic syndrome, smoking and alcohol consumption in psoriasis patients and the relationship between disease severity and these factors. Methods: This cross-sectional study enrolled 563 patients with chronic plaque-type psoriasis, all of which completed a questionnaire and underwent a complete physical examination. Data about MBS components, psoriasis severity/duration, smoking and alcohol consumption, and cardiovascular diseases were recorded. Results: A total of 563 patients with ages ranging from 18 to 78 years were evaluated. Metabolic syndrome was found in 12.6% of the patients [central obesity (38.7%), hypertension (14.3%), dyslipidemia (18.6%), diabetes (9.2%)], while 50.3% had smoking, and 3.3% had alcohol consumption. Patients with metabolic syndrome were older and more likely to have a longer disease duration than those without metabolic syndrome (p<0.05 for each). The prevalence of metabolic syndrome was higher in women than in men. Psoriasis was more severe in patients with central obesity, diabetes and smoking than in those without (p<0.05 for each). Study Limitations: Retrospective design. Conclusions: Our results indicate that MBS is a risk factor for psoriasis patients with advanced age. The relationship between disease severity and obesity, diabetes, and smoking in psoriasis patients indicates that the patients should be informed about the potential metabolic risks and receive therapies for behavioral changes besides anti-psoriatic treatment in order to minimize these risks.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Adulto Jovem , Psoríase/epidemiologia , Consumo de Bebidas Alcoólicas/epidemiologia , Fumar/epidemiologia , Síndrome Metabólica/epidemiologia , Psoríase/complicações , Fatores de Tempo , Turquia/epidemiologia , Consumo de Bebidas Alcoólicas/efeitos adversos , Doenças Cardiovasculares/etiologia , Fumar/efeitos adversos , Fatores Sexuais , Métodos Epidemiológicos , Fatores de Risco , Fatores Etários , Distribuição por Sexo , Distribuição por Idade , Síndrome Metabólica/complicações , Diabetes Mellitus/epidemiologia , Dislipidemias/complicações , Dislipidemias/epidemiologia , Obesidade Abdominal/complicações , Obesidade Abdominal/epidemiologia , Hipertensão/complicações , Hipertensão/epidemiologiaRESUMO
BACKGROUND: Phototherapy has been the mainstay of therapies for early mycosis fungoides (MF). The beneficial role of ultraviolet (UV) light on MF is suggested by the observation that lesions occur on non-sun-exposed areas. Therapeutic light sources that are available today are broadband UVB, psoralen and UVA, narrowband UVB, and long-wave UV (UVA1). Current literature provides increasing evidence on the use of UVA1 to treat MF. AIM: To investigate the treatment responses of early MF patients treated with fixed 30 J/cm2 doses of UVA1 phototherapy. MATERIAL AND METHODS: Nineteen patients with early MF, stage IA-IIA of the TNM staging system, received fixed 30 J/cm2 doses of UVA1, given 5 times weekly over 5 weeks. Therapeutic effectiveness was assessed by clinical examination and was confirmed by histological evaluation. RESULTS: Of the 19 patients, complete responses were achieved in 12 (63%) and partial responses were achieved in 7 (37%) patients after UVA1 radiation exposures. During the study, UVA1 therapy was well tolerated. During the follow-up, 7 (58%) of the 12 patients with complete response relapsed within 3 months of the UVA1 therapy. CONCLUSION: The current study provides clinical and histological evidence for the effectiveness of UVA1 (30 J/cm2 5 times a week for 5 weeks) as a skin-directed therapy in the treatment of early MF; however, such a treatment failed to maintain a long and sustained response. Thus, studies to identify the optimal dosing protocol regarding the therapeutic efficacy, the factors affecting relapse time/rate, and the necessity of maintenance treatment are needed.
Assuntos
Micose Fungoide/radioterapia , Recidiva Local de Neoplasia , Neoplasias Cutâneas/radioterapia , Terapia Ultravioleta , Humanos , Micose Fungoide/patologia , Estadiamento de Neoplasias , Neoplasias Cutâneas/patologia , Resultado do TratamentoRESUMO
Acrodermatitis continua of Hallopeau (ACH) is a variant of pustular psoriasis that is often very difficult to treat. Almost all anti-psoriatic agents have been used in the treatment of ACH. Ustekinumab, a fully human monoclonal antibody of the IgG1 class, is directed to the shared p40 subunit of cytokines IL-12 and IL-23. Herein, we present our experience of ustekinumab use in a 50-year-old man who was resistant to anti-tumor necrosis factor-α agents. Though initial therapy with ustekinumab achieved a sustained response in our patient, after a seven months of interruption, retreatment resulted in a slower and poorer response than the initial regimen. Both responses of our patient reflects: (i) the recalcitrant chronic nature of ACH in some patients, (ii) the value of ustekinumab in ACH treatment, (iii) the fact that, as with other biologics, a loss of response may also occur with ustekinumab when the treatment is interrupted. All these data provides evidence for the fact that the course of ACH is unpredictable and possibly indicate that concerning current biologics used in the treatment of ACH, we have still failed to hit the target we aimed for.
Assuntos
Acrodermatite/tratamento farmacológico , Produtos Biológicos/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Resistência a Medicamentos , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Ustekinumab/uso terapêutico , Acrodermatite/diagnóstico , Acrodermatite/imunologia , Substituição de Medicamentos , Humanos , Masculino , Pessoa de Meia-Idade , Indução de Remissão , Resultado do Tratamento , Fator de Necrose Tumoral alfa/imunologiaRESUMO
The aim of this study was to document the profile of pyoderma gangrenosum (PG) patients who were treated in our clinic and to compare our patients' clinical and demographic characteristics with those described in the literature to help our understanding of the total burden of PG. A total of 27 (17 women, 10 men) patients with a mean age 48.6 years at diagnosis were included in the study. Seven (25.9%) of them had 3 or more ulcers. The lower extremity was the most common site of occurrence (92.5%). During the study period, 6 patients were admitted twice, and 7 were admitted 3 or more times (range 1 to >10), and the median length of stay was 27 days. A concomitant disease was present in PG patients especially in those between 20 and 40 years of age. Systemic therapy was used in 21 (91.3%) patients, 17 patients were treated with systemic corticosteroids, either alone in 7 patients or combination with other agents in 10 patients. Three of our patients died because of disease or treatment-related complications during the study period. Despite the high (70.3%) percentage of the PG patients with improving disease at the time of discharge, 1 year after hospital discharge, one third of our 27 patients still had PG requiring readmission. In conclusion, none of the current therapies provide satisfying results in all of the patients, and our data indicate a long-standing unmet need for effective therapy for the unexpected course of PG.
Assuntos
Efeitos Psicossociais da Doença , Glucocorticoides/uso terapêutico , Úlcera da Perna , Pioderma Gangrenoso , Tratamento Conservador/métodos , Feminino , Humanos , Úlcera da Perna/etiologia , Úlcera da Perna/terapia , Tempo de Internação/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Readmissão do Paciente/estatística & dados numéricos , Pioderma Gangrenoso/complicações , Pioderma Gangrenoso/diagnóstico , Pioderma Gangrenoso/mortalidade , Pioderma Gangrenoso/terapia , Estudos Retrospectivos , Turquia/epidemiologiaRESUMO
Psoriasis is a common inflammatory disease that has a severe impact on quality of life. There is lack of data regarding epidemiological and clinical features of psoriasis patients in Turkey, a country with a population of 76 million. The aim of this study was to define the demographic and clinical characteristics, quality of life and treatment patterns of psoriasis patients in Turkey. A cross-sectional observational study was conducted at 40 centers, chosen from geographically diverse locations in Turkey. Patients diagnosed with psoriasis were assessed by investigators who were specialists of dermatology using standardized study questionnaire forms. Dermatology Life Quality Index (DLQI) and EuroQol-5 dimension (EQ-5D) forms were also filled out by each patient. 3971 psoriasis patients were included in this study. 24.2% of plaque psoriasis patients had moderate to severe psoriasis (Psoriasis Area and Severity Index, ≥10). Mean DLQI was 7.03 ± 6.02; quality of life was moderately, severely or very severely affected in 49.2% of patients. The most severely affected component of EQ-5D was anxiety/depression. Among all patients, 22.9% were not receiving any treatment, 39.8% were receiving only topical treatment, 11.5% were on phototherapy, 26.1%, were taking conventional systemic agents and 4.1% were on a biologic treatment. 31.3% of psoriasis patients with moderate to severe disease were treated with only topical agents and only 30.5% of moderate to severe psoriasis patients were receiving systemic therapy. Moderate to severe psoriasis has a considerable impact on quality of life. Treatment in Turkey of patients with moderate to severe psoriasis is insufficient.
Assuntos
Psoríase/terapia , Adolescente , Adulto , Ansiedade/etiologia , Produtos Biológicos/uso terapêutico , Estudos Transversais , Fármacos Dermatológicos/administração & dosagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fototerapia , Psoríase/patologia , Psoríase/psicologia , Qualidade de Vida , Turquia , Adulto JovemRESUMO
Prolidase deficiency is an autosomal recessive disorder, which is associated with chronic skin ulcers, a characteristic facial appearance, mental retardation, and recurrent infections. This study describes 4 patients with recurrent leg ulcerations and abnormal facies who were first clinically suspected of prolidase deficiency and then biochemically confirmed. Two siblings and 2 other patients were admitted to our clinic at different times, and they had some common features such as chronic leg and foot ulcers recalcitrant to treatment, consanguineous parents, facial dysmorphism, mental retardation, and widespread telangiectasias. Physical examination and detection of low prolidase level in blood finally led us to the diagnose of ulcers secondary to prolidase deficiency. Prolidase deficiency is a rare genodermatosis and must be considered in the differential diagnosis of recurrent leg and foot ulcers that develop at an early age.
Assuntos
Úlcera da Perna/etiologia , Deficiência de Prolidase/complicações , Adolescente , Adulto , Feminino , Humanos , Úlcera da Perna/patologia , Masculino , Adulto JovemRESUMO
The degradation of the main fibrillar collagens, collagens I and II, is a crucial process for skeletal development. The most abundant dipeptides generated from the catabolism of collagens contain proline and hydroxyproline. In humans, prolidase is the only enzyme able to hydrolyze dipeptides containing these amino acids at their C-terminal end, thus being a key player in collagen synthesis and turnover. Mutations in the prolidase gene cause prolidase deficiency (PD), a rare recessive disorder. Here we describe 12 PD patients, 9 of whom were molecularly characterized in this study. Following a retrospective analysis of all of them a skeletal phenotype associated with short stature, hypertelorism, nose abnormalities, microcephaly, osteopenia and genu valgum, independent of both the type of mutation and the presence of the mutant protein was identified. In order to understand the molecular basis of the bone phenotype associated with PD, we analyzed a recently identified mouse model for the disease, the dark-like (dal) mutant. The dal/dal mice showed a short snout, they were smaller than controls, their femurs were significantly shorter and pQCT and µCT analyses of long bones revealed compromised bone properties at the cortical and at the trabecular level in both male and female animals. The differences were more pronounce at 1 month being the most parameters normalized by 2 months of age. A delay in the formation of the second ossification center was evident at postnatal day 10. Our work reveals that reduced bone growth was due to impaired chondrocyte proliferation and increased apoptosis rate in the proliferative zone associated with reduced hyperthrophic zone height. These data suggest that lack of prolidase, a cytosolic enzyme involved in the final stage of protein catabolism, is required for normal skeletogenesis especially at early age when the requirement for collagen synthesis and degradation is the highest.
Assuntos
Osso e Ossos/patologia , Dipeptidases/metabolismo , Deficiência de Prolidase/metabolismo , Adolescente , Adulto , Animais , Sequência de Bases , Tamanho Corporal , Criança , Pré-Escolar , Citosol/enzimologia , Feminino , Fêmur/patologia , Fibroblastos/enzimologia , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C3H , Camundongos Endogâmicos CBA , Camundongos Transgênicos , Dados de Sequência Molecular , Osteoblastos/enzimologia , Fenótipo , Estrutura Terciária de Proteína , Estudos Retrospectivos , Tíbia/patologia , Tomografia Computadorizada por Raios X , Microtomografia por Raio-X , Adulto JovemRESUMO
Trichofolliculoma is a rare hair follicle hamartoma, which is often regarded as a hair follicle tumor. Mostly, it presents as a papule or nodule, involving the skin of the face and scalp area. A central, dilated keratin plugged ostium with vellus hair(s) is often present. We report a 19-year-old woman with typical clinical and histopathological findings of trichofolliculoma.
Assuntos
Cisto Folicular/patologia , Cisto Folicular/cirurgia , Neoplasia de Células Basais/patologia , Neoplasia de Células Basais/cirurgia , Couro Cabeludo , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/cirurgia , Adulto , Feminino , Neoplasias de Cabeça e Pescoço/patologia , Neoplasias de Cabeça e Pescoço/cirurgia , Humanos , Recidiva Local de Neoplasia/diagnóstico , Adulto JovemRESUMO
Although the mechanisms underlying the loss of response to infliximab are not completely understood, the formation of antibodies to infliximab (ATI) are thought to play a role. The aim of this study was to investigate the presence of ATI in psoriatic patients and to evaluate its relationship to the clinical response. Fifteen patients with psoriasis were treated with infliximab (5 mg/kg) every 8 weeks after an initial three-dose induction treatment. An enzyme linked immunosorbent assay kit was used for analyzing the presence of ATI in sera. Effectiveness assessments included the change in Psoriasis Area and Severity Index (PASI) compared with study entry. Five (33.3%) patients developed ATI. While 5.9 +/- 3.2 infliximab infusions achieved a fall in the PASI score from a mean of 20.4 +/- 8.3 to 5.3 +/- 2.4 in ATI-negative patients, these values changed from 23.3 +/- 11 to 10 +/- 4.9 after 9 +/- 5.2 infusions in ATI-positive patients. Our results suggested that ATI measured in psoriatic patients are of clinical importance. Therefore, monitoring for the induction of ATI and rescue strategies should be developed to avoid or to maintain a delay in ATI development.
Assuntos
Anticorpos Monoclonais/imunologia , Anticorpos/imunologia , Fármacos Dermatológicos/imunologia , Psoríase/terapia , Corticosteroides/uso terapêutico , Idoso , Anticorpos/sangue , Anticorpos Monoclonais/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Feminino , Humanos , Infliximab , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Psoríase/imunologia , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
In order to investigate a possible link between parasites and chronic urticaria, the prevalence of intestinal protozoans in stool samples of individuals with chronic urticaria (n=55) and healthy controls (n=43) were evaluated with native lugol, formol-ethyl acetate concentration and trichrom dye, modified acid fast. In the case of Giardia intestinalis (G. intestinalis) ELISA was also used. In the study 29.1% of the patients were found to have protozoan (Blastocystis hominis + G.intestinalis) infections. On the other hand, only 11.6% of the patients in healthy group were having a protozoon infection, all of which were B. hominis. There was no statistically significant difference between the patient group and control group regarding the frequency of B. hominis presence. Also, the number of G.intestinalis positive patients were also statistically different in patient group from those of healthy controls. In patients whom were positive for protozoan infections, agent specific therapy was used. In 7 of these patients symptoms of the disease were subsided with this therapy while six continued to have relapses. Three patients had missed the control visits therefore the course of the disease was not evaluated. As a conclusion, protozoans should be considered in the etiology of chronic urticaria and stool examination should be done in these patients routinely.
Assuntos
Enteropatias Parasitárias/complicações , Infecções por Protozoários/complicações , Urticária/parasitologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Infecções por Blastocystis/complicações , Infecções por Blastocystis/epidemiologia , Blastocystis hominis/isolamento & purificação , Estudos de Casos e Controles , Criança , Fezes/parasitologia , Feminino , Giardia lamblia/isolamento & purificação , Giardíase/complicações , Giardíase/epidemiologia , Humanos , Enteropatias Parasitárias/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Infecções por Protozoários/epidemiologia , Turquia/epidemiologia , Adulto JovemAssuntos
Edema/etiologia , Veia Ilíaca , Trombose Venosa/diagnóstico , Abdome , Adulto , Anticoagulantes/uso terapêutico , Feminino , Humanos , Imageamento por Ressonância Magnética , Nadroparina/uso terapêutico , Complicações Pós-Operatórias , Trombectomia , Ultrassonografia Doppler , Trombose Venosa/terapiaRESUMO
BACKGROUND: Topical tetracycline was the first topical antibiotic approved for the treatment of acne, its use has been limited because of the skin penetration problems of the active ingredient. OBJECTIVES: The objective of this study was to evaluate the effectiveness of a new formulation of topical tetracycline [Imex, tetracycline hydrochloride 3%, 20g] monotherapy in the treatment of mild to moderate acne vulgaris. METHODS: The sample group consisted of 87 volunteer students of both sexes with grade 1 to grade 2 acne as assessed by Investigator's Global Assessment (IGA) severity grading system. Subjects were instructed to apply topical tetracycline twice daily for 8 weeks. Subject were evaluated at baseline and at weeks 2, 4, and 8. RESULTS: Of 87 subjects, 68 completed the 8-week treatment period. The mean reduction rates of opened comedones were 55.4%, closed comedones were 27.1%, papules were 24.8%, pustules were 27.3%. After 8 weeks of treatment, a statistically significant reduction was only observed in the mean counts of the papules and pustules (P < 0.001). CONCLUSION: Tetracycline is a well-tolerated topical agent and is particularly effective in the treatment of inflammatory lesions in acne.
Assuntos
Acne Vulgar/tratamento farmacológico , Anti-Infecciosos Locais/uso terapêutico , Tetraciclina/uso terapêutico , Acne Vulgar/patologia , Administração Tópica , Adolescente , Adulto , Anti-Infecciosos Locais/administração & dosagem , Interpretação Estatística de Dados , Feminino , Humanos , Masculino , Cooperação do Paciente , Tetraciclina/administração & dosagem , Adulto JovemRESUMO
A 50-year-old woman who presented with intermittent symmetric edema and wrinkling of the palms after soaking in water was found to have transient reactive papulotranslucent acrokeratoderma (TRPA). This is the oldest patient ever reported to have this condition. The patient was advised to avoid water exposure as much as possible and to wear gloves. Topical treatment with 5% salicylic acid in Vaseline also provided some relief. TRPA presents with translucent, white, confluent papules that become evident on the palms after 3-5 minutes' exposure to water (the so-called 'hand-in-the-bucket' sign) and resolve within a short time after drying. It is a rare disorder with fewer than 40 cases having been reported in the world literature. The disease is seen mostly in female patients, with ages ranging from 6 to 44 years prior to our case in a 50-year-old woman. The most common histologic findings are hyperkeratosis and dilated eccrine ostia. The etiopathogenesis of the disease remains unknown but a transitory structural or functional alteration of components of the stratum corneum or aberration of the sweat duct have been considered. TRPA has been reported in patients with cystic fibrosis and more recently, in patients taking selective cyclo-oxygenase-2 inhibitors. Therefore, the pathogenesis of the condition appears to be related to increased water absorption as a result of an increased epidermal sodium level. Treatment with barrier creams such as hydrophilic petrolatum, glycerin emollients, 5-20% salicylic acid in Vaseline, 10% urea cream, and 12% ammonium lactate cream have been reported. Cases with associated hyperhidrosis respond well to aluminum chloride-containing products.
Assuntos
Ceratodermia Palmar e Plantar/patologia , Administração Tópica , Edema/patologia , Feminino , Glicerol/administração & dosagem , Glicerol/uso terapêutico , Humanos , Ceratodermia Palmar e Plantar/tratamento farmacológico , Ceratodermia Palmar e Plantar/epidemiologia , Masculino , Pessoa de Meia-Idade , Vaselina/administração & dosagem , Vaselina/uso terapêutico , Ácido Salicílico/administração & dosagem , Ácido Salicílico/uso terapêutico , Caracteres Sexuais , Água/efeitos adversosRESUMO
Insulin-like growth factor (IGF) and its binding proteins (BPs) are candidates to play a role in the pathogenesis of psoriasis. IGF-I and -II and their binding proteins (IGFBPs) have both growth inhibitory and mitogenic effects on a multitude of cell types. Current studies have explored the potential role of IGFBP-3 in keratinocyte growth and differentiation. To gain more insight into the role of IGFBP-3 in the pathogenesis of psoriasis, we investigated the changes in IGFBP-3 expression levels in psoriatic plaque and compared these expressions with levels in other inflammatory skin diseases. In particular, we investigated whether or not the changes in IGFBP-3 were affected by systemic treatment with cyclosporine A (CsA) or methotrexate (Mtx). We found significantly increased IGFBP-3 expression levels in the psoriatic group compared with levels in patients with other, nonproliferative inflammatory skin diseases, and we demonstrated differences in distribution pattern before and after systemic treatment with Mtx or CsA. Mtx and CsA had no effect on tissue IGFBP-3 expression levels. Before treatment with Mtx or CsA, IGFBP-3 expression was limited to the basal layer and suprapapillary region. Unlike with Mtx, CsA significantly changed the IGFBP-3 distribution pattern.